The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) recently awarded $3.7 million to support a project led by principal investigator and assistant professor of biomedical research, Chase Kessinger, Ph.D. Awarded a grant. The Department of Translational Medicine at the Masonic Medical Research Institute (MMRI) studies pulmonary embolism (PE), the third most common cause of cardiovascular death.
The five-year study aims to use advanced imaging techniques to understand how blood clot size and age affect lung inflammation and scarring. Advanced imaging techniques may also allow researchers to measure the effectiveness of promising thrombolytic therapies.
PE is a disease in which one of the pulmonary arteries in the lungs suddenly becomes blocked. This is usually caused by a blood clot that travels from deep veins to the lungs, preventing blood from flowing properly. This often occurs when you are stationary for long periods of time, such as when traveling long distances, and reduced blood flow can lead to complications.
PE is a devastating cardiovascular disease that can cause significant reductions in quality of life and chronic, long-term limitations. This project aims to help clinicians better diagnose and treat PE patients. ”
Dr. Chase Kessinger, Assistant Professor of Biomedical Research and Translational Medicine, Masonic Medical Institute
Kessinger specializes in integrating translational imaging technologies and new diagnostic and therapeutic agents for the research and treatment of cardiovascular diseases. His current research aims to understand the biology of PE, pulmonary hypertension, and its inflammatory response. His hope is to find tools to better identify and target blood clots to prevent PE.
“We are doing groundbreaking research here in the Mohawk Valley,” Kessinger said. “This funding allows us to support Utica’s talented scientists and their innovative projects, helping our world-class scientific community thrive.”
“We would like to thank the NHLBI for supporting Dr. Kessinger’s research,” said Maria Kontaridis, executive director of MMRI, professor of biomedical research and translational medicine, and the Gordon K. Moe Professor. the doctor said. “We are confident that this research will have a deep and lasting impact on the future of cardiovascular health.”
sauce:
Freemason Medical Institute
